|Day Low/High||119.16 / 120.85|
|52 Wk Low/High||60.30 / 125.49|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CRVL, INCY, WHLR Downgrades: BABA, FLO, ITT, TPX Initiations: AUXO Read on to get TheStreet Quant Ratings' detailed report:
Incyte Corporation (Nasdaq:INCY) and Agenus Inc. (Nasdaq:AGEN) announced today that the companies have amended the License, Development and Commercialization Agreement that was originally entered into January 9, 2015.
Incyte Corporation (Nasdaq:INCY) today reports 2016 fourth-quarter and year-end financial results, highlighting strong revenue growth driven by increased sales of Jakafi ® (ruxolitinib) in the U.
U.S. stock futures are declining Tuesday while European and Asian shares trade mixed ahead of congressional testimony from Federal Reserve Chair Janet Yellen.
Fed Chair Janet Yellen will give her two-day semiannual monetary policy testimony, while major economic data will drive markets.
Incyte Corporation (NASDAQ:INCY) and Calithera Biosciences, Inc. (NASDAQ:CALA) announce today that the companies have entered into a global collaboration and license agreement for the research, development and...
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter and year end 2016 financial results conference call and webcast for 10:00 a.
Animal health and oncology deal activity is heating up in 2017.
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
The companies will study epacadostat in tandem with Merck's Keytruda in patients with non-small cell lung, renal, bladder and head and neck cancers.
Deals, though, weren't the only mover of share prices.
Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of...
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
Incyte Corporation (Nasdaq:INCY) today announced that the first patient has been treated in the REACH-1 pivotal Phase 2 trial evaluating ruxolitinib (Jakafi ®) in combination with corticosteroids for the treatment of...
Incyte Corporation (NASDAQ:INCY) and Merus N.V.
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 35 th Annual J.
Incyte Corporation (Nasdaq:INCY) today announces an exploratory pooled analysis of data from the five-year follow-up of the Phase 3 COMFORT-I and COMFORT-II trials which further supports previously published overall...
With the election resolved, biotech could be ripe for consolidation.
Prices have marched their way all the way back up to the bottom end of key resistance.
For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!
Investors have convinced themselves that President Donald Trump is going to make drug stocks great again. Will it last?
The most recent short interest data has been released for the 10/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Incyte Corporation (Nasdaq: INCY) announces that more than 20 abstracts including data from its ongoing clinical development program for Jakafi ® (ruxolitinib) and its small molecule development programs targeting...
Incyte Corporation (Nasdaq:INCY) announced today that it will present at the 28 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016 at 11:30 am (EST) in New York.